Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities

Canadian Journal of Psychiatry

Volumn 46, Issue 8, 2001, Pages 741-745

  Robin, Friedlander ^a,b   Susan, Lazar ^a   Joseph, Klancnik ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b West Coast and Fraser Valley Mental Health Teams   (Canada)

Author keywords

Adolescents; Atypical neuroleptics; Developmental disabilities; Dyskinesias; Mental retardation

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADOLESCENT; ADULT; AKATHISIA; ARTICLE; DEVELOPMENTAL DISORDER; DRUG EFFICACY; DRUG MONITORING; DRUG USE; DYSKINESIA; DYSTONIA; FEMALE; GALACTORRHEA; HEADACHE; HUMAN; LETHARGY; MAJOR CLINICAL STUDY; MALE; MENTAL DEFICIENCY; NAUSEA; SIDE EFFECT; TREMOR; VERTIGO; WEIGHT GAIN;

EID: 0035194171     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674370104600807     Document Type: Article

References (25)

1. Pharmacotherapy in mental retardation
2. A national study of prescribed drugs in institutions and community residential facilities for mentally retarded people
3. TMS: A system for prevention and control
4. Antipsychotics in children and adolescents
5. Pharmacologic interventions
6. Effects of thioridazine dosage on the behavior of severely retarded persons
7. Neuroleptic related dyskinesias in autistic children: A prospective, longitudinal study
8. Subtle and unrecognized side effects of neuroleptic treatment in children with Tourette disorder
9. Repeated episodes of neuroleptic related dyskinesias in autistic children
10. Tardive and withdrawal dyskinesias in autistic children: A prospective study
11. Tardive dyskinesia in mentally retarded children, adolescents and young adults: North Carolina and Michigan studies
12. Methylphenidate and haloperidol in children: Effects on attention, memory and activity
13. Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette syndrome
14. Children with schizophrenia: Diagnosis, phenomenology and pharmacotherapy
15. Behavioral efficacy of haloperidol and lithium carbonate: A comparison in hospitalized aggressive children with conduct disorder
16. Haloperidol in the treatment of children with severe behaviour disorders
17. Risperidone: An analysis of the first three years of general use
18. A double blind placebo controlled trial of risperidone in adults with autistic disorder and other pervasive developmental disorders
19. A brief review of atypical neuroleptics in individuals with developmental disability
20. Blind controlled long term study of the comparative incidence of treatment emergent tardive dyskinesia with olanzapine or haloperidol
21. Brief report: Risperidone for severely disturbed behaviour and tardive dyskinesia in developmentally disabled adults
22. Risperidone treatment of children and adolescents: Increased risk of extrapyramidal side effects
23. Developmental toxicology
24. Mental retardation and psychiatric illness